LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.
All of the 400 subjects required for the study were enrolled and samples will be taken from them for evaluation. Angle intends to submit to the US Food & Drug Administration for approval of the technology mid-year.
Angle is a liquid biopsy company, which engages in the use of fluid, such as blood, to diagnose conditions rather than tissue samples. Angle's Pasortix system is used to separate cancer cells that are circulating in the blood so that they can be analysed.
"Completion of the enrolment for our Parsortix FDA clinical study is a key milestone for Angle. We believe there is a tremendous opportunity for Angle to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer," said Angle Founder & Chief Executive Andrew Newland.
Shares in Angle were down 2.5% at 59.00 pence in London on Thursday.
Angle (AGL)